Tilray Launches ATM Equity Program to Fund Expansion

The latest update is out from Tilray ( (TLRY) ).

On April 15, 2026, Tilray Brands detailed a series of moves to drive its next phase of global expansion, led by the acquisition of U.K.-based Lyphe Group, a medical cannabis clinic and digital pharmacy platform that has dispensed about 150,000 units and treated more than 16,000 patients. The deal creates Tilray’s first fully vertically integrated, patient-centric medical platform in the U.K. by combining cultivation, clinical care, dispensing services, and pharma distribution, and management expects the Lyphe business to become accretive in 2027 while strengthening Tilray’s European healthcare footprint.

Six weeks after acquiring craft brewer BrewDog, Tilray said it has stabilized brewing volumes, maintained service levels, and started onboarding new distribution partners as it invests to revive the brand’s brewpub estate and reposition the business for long-term growth. The company aims to rebuild BrewDog toward its prior $1 billion valuation, expects the unit to be cash flow positive in 2027, plans a “brewpub of the future” concept, and will leverage the platform to scale its broader beverage portfolio, including launching Hi*Ball Energy in the U.K. in May.

Tilray also highlighted its preparations for a potential U.S. rescheduling of medical cannabis, arguing its experience in highly regulated markets, pharmaceutical-grade cultivation and manufacturing, and clinical research across more than 20 markets position it to participate in a future regulated U.S. medical cannabis market. The company is monitoring policy developments, engaging with lawmakers and regulators, and evaluating participation in a federal pilot program that could expand access to hemp-derived medical cannabis for underserved patients.

To fund these initiatives and bolster balance-sheet flexibility, Tilray entered into an at-the-market equity program on April 15, 2026, allowing it to sell up to $180 million in common stock through Jefferies, TD Securities (USA), and Roth Capital Partners as agents. The ATM facility, which can be tapped opportunistically under an effective shelf registration, is intended to support investments in the company’s global beverage platform and align capital deployment with evolving market conditions and strategic priorities.

The most recent analyst rating on (TLRY) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Tilray stock, see the TLRY Stock Forecast page.

Spark’s Take on TLRY Stock

According to Spark, TipRanks’ AI Analyst, TLRY is a Neutral.

TLRY scores low primarily due to persistent large losses and ongoing negative free cash flow, which outweigh recent revenue scaling and reduced leverage. Technicals add further pressure as the stock is in a clear downtrend with weak momentum. Offsetting factors include improving adjusted EBITDA trends and reaffirmed guidance from the earnings call, but execution, cash-flow durability, and regulatory/integration risks remain material.

To see Spark’s full report on TLRY stock, click here.

More about Tilray

Tilray Brands, Inc., listed on Nasdaq and the TSX under TLRY, is a global lifestyle and consumer packaged goods company focused on cannabis, beverages, and wellness products. The company operates medical cannabis platforms, craft beverage brands, and pharmaceutical distribution networks, with a growing presence across Europe, the U.K., North America, and other international markets.

Average Trading Volume: 2,950,950

Technical Sentiment Signal: Sell

Current Market Cap: $783.2M

For a thorough assessment of TLRY stock, go to TipRanks’ Stock Analysis page.